Kuwait

The primary regulatory authority governing health products in Kuwait is the Drug and Food Control General Administration (DFCGA), operating under the Ministry of Health (MOH). The DFCGA is responsible for the registration, licensing, and post-market surveillance of pharmaceuticals, medical devices, diagnostics, and increasingly digital health solutions. The overarching legislative framework is grounded in Decree Law No. 34 of 1981 and its subsequent amendments, supplemented by ministerial circulars and technical guidelines that govern product registration, import controls, and market authorization. All health products must obtain a valid registration certificate from the DFCGA before they can be legally marketed or procured within Kuwait. The approval process generally involves a dossier review phase, an assessment of product safety and efficacy data, and in some cases a local conformity inspection or laboratory testing requirement before a marketing authorization is granted.

Applicants seeking registration in Kuwait are required to appoint a locally registered Kuwaiti agent or authorized representative, who acts as the legal liaison with the DFCGA throughout the submission and post-approval lifecycle. Dossier submissions are expected to follow the Common Technical Document (CTD) format for pharmaceuticals, while medical devices and diagnostics are evaluated against international standards such as those issued by the ISO and, where applicable, conformity with CE marking or US FDA clearance, which can facilitate the review process. Kuwait is a member of the Gulf Cooperation Council (GCC) and participates in the GCC Centralized Drug Registration (CDR) program administered by the Gulf Health Council, allowing products registered through the CDR pathway to benefit from a harmonized regional review that can streamline national authorization in Kuwait. Recent reforms have focused on accelerating review timelines for products that hold prior approval from recognized stringent regulatory authorities (SRAs) such as the US FDA, EMA, or Health Canada, and the MOH has shown increasing interest in developing a dedicated regulatory pathway for digital health and software as a medical device (SaMD).

Public procurement of health products in Kuwait is highly centralized and dominated by the Ministry of Health, which serves as the principal buyer for the public healthcare system encompassing government hospitals, polyclinics, and primary health centers. The Central Medical Stores (CMS) under the MOH manages the warehousing and distribution of centrally procured health commodities. Procurement is conducted through formal tendering processes overseen by the Central Tenders Committee (CTC), which is the national body responsible for evaluating and awarding public contracts above defined financial thresholds. Tenders are typically published in official government channels and the Kuwait Official Gazette, and suppliers must be locally registered and work through an authorized Kuwaiti agent or distributor to participate. Framework agreements and direct procurement mechanisms may be used for urgent or specialized health needs, and price negotiation plays an important role in high-value categories such as oncology pharmaceuticals and advanced medical devices. Public procurement decisions are also influenced by the Kuwaiti National Formulary, which determines which products are eligible for government reimbursement and purchase.

The private healthcare sector in Kuwait is a growing procurement channel, comprising private hospitals, specialist clinics, pharmacies, and diagnostic laboratories that procure health products independently through local distributors and direct supplier agreements. Private sector procurement is less price-controlled than the public sector and can offer faster market access for premium or innovative products. Kuwait does not participate extensively in donor-funded procurement mechanisms such as those administered by UNICEF Supply Division, the Global Fund, Gavi, or USAID, given its high-income status; the vast majority of health product procurement is financed directly through the national budget. Kuwait does not currently enforce explicit local manufacturing preference policies in procurement, though there are broader national economic diversification ambitions under Kuwait Vision 2035 that encourage investment in domestic pharmaceutical and healthcare manufacturing capabilities, which may influence future procurement policy directions.